ea0090ep437 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023
Ferrer Garcia Juan Carlos
, Albalat-Galera Raquel
, Moya Victor Atienza
, Hernandez Jessica Sanchez
, Palomar Luis Arribas
, Casamayor Ignacio Ramos
, Fullana Ana Artero
, Blanco Cintia Gonzalez
, Portilla Ana Jimenez
, Juan Carlos Sanchez
Background and Objective: Semaglutide, a glucagon-like peptide 1 (GLP1a) receptor agonist, reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus (DM2). An oral version of semaglutide is now available, and patients may prefer it to the subcutaneous form. Our objective was to compare the effectiveness and safety of both formulations in real life.Methods: Retrospective real-world efficacy analysis including aGLP1-...